Progestin Drug Class List

Drugs in Drug Class: Progestin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Technologies	XULANE	ethinyl estradiol; norelgestromin	FILM, EXTENDED RELEASE;TRANSDERMAL	200910-001	Apr 16, 2014	AB	RX	No	Yes
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes	8,747,888		Y
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes	8,246,978		Y
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes	9,050,348		Y
Bayer Hlthcare	SKYLA	levonorgestrel	SYSTEM;INTRAUTERINE	203159-001	Jan 9, 2013		RX	Yes	Yes	11,850,182		Y
Bayer Hlthcare	SKYLA	levonorgestrel	SYSTEM;INTRAUTERINE	203159-001	Jan 9, 2013		RX	Yes	Yes	10,561,524
Bayer Hlthcare	SKYLA	levonorgestrel	SYSTEM;INTRAUTERINE	203159-001	Jan 9, 2013		RX	Yes	Yes	11,628,088		Y

Market Dynamics and Patent Landscape for Progestin Drugs

Last updated: March 26, 2026

What Are the Key Market Drivers for Progestin Drugs?

The global market for progestin drugs is driven by their broad use in contraception, hormone replacement therapy (HRT), and the treatment of certain gynecological conditions. The increasing prevalence of menstrual disorders, osteoporosis, and menopausal symptoms, alongside expanding aging populations, sustains demand growth.

• The worldwide contraceptive market was valued at approximately $22 billion in 2022, with progestins representing a significant segment (Grand View Research, 2023).
• The prevalence of menopause-related hormone therapy users is projected to grow at a compound annual growth rate (CAGR) of around 4% through 2030 (Research and Markets, 2023).
• Rising awareness and acceptance of hormonal contraceptives, especially in developing nations, amplify market expansion.

What Are the Trends Influencing Market Dynamics?

1. Generic Competition
   Patent expirations for blockbuster progestins have led to increased generic product entry, reducing prices and squeezing profitability for innovative firms.

2. Innovation in Delivery Systems
   Advances include extended-release implants, intrauterine devices (IUDs), and transdermal patches, offering improved compliance and convenience, influencing market segmentation.

3. Regulatory Environment
   Variability in regulatory approval processes across regions influences the pace of new product launches. Countries like the U.S. and Europe maintain rigorous standards, impacting time-to-market.

4. Emerging Markets
   Growth in Asia-Pacific, Latin America, and Africa accounts for a rising share of global progestin consumption, driven by population growth and increased healthcare access.

What Does the Patent Landscape Look Like?

Patent Term and Expiry Trends

Most patents protecting progestin compounds or formulations entered expiration phases between 2010 and 2025. Key drug patents have been or are set to expire, opening markets for generics.

Drug Name	Original Patent Expiry	Generic Entry	Notes
Medroxyprogesterone acetate	2010–2015	Multiple generics since 2016	Widely used in injectable HRTs
Norethindrone	2005–2015	Present	Patents associated with specific formulations expire at different times
Desogestrel	2010	Several generics available	First-generation progestin with patent protections expiring early 2010s

Key Patent Filings and Litigation

• Innovative developments revolve around new delivery mechanisms, such as subdermal implants (e.g., etonogestrel implants) with patent protections extending into the late 2020s.
• Patent litigations mainly involve disputes over formulation exclusivity and delivery system patents, with some institutions challenging patent validity to facilitate generics.

Patent Strategies by Innovators

• Many companies secure patents for combination formulations, novel delivery systems, and optimized bioavailability.
• Some patent portfolios extend over 20 years, covering various aspects of formulations, methods of use, and manufacturing processes to maximize market exclusivity.

How Do Regulatory Policies Impact the Landscape?

• The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) grant chemical, formulation, and device approvals, influencing patent lifecycle management.
• Patent linkage and data exclusivity periods in major markets delay generic entry even after patent expiry.
• Countries with accelerated approval pathways and weaker patent enforcement can facilitate faster generic and biosimilar entry.

What Are the Opportunities and Challenges?

Opportunities

• Development of long-acting reversible contraceptives (LARCs) with proprietary delivery systems.
• Expansion into emerging markets with unmet needs for contraceptive options.
• Innovation in hormonal combination therapies for gynecological and menopausal indications.

Challenges

• Patent cliffs after expiry of primary progestins threaten revenue streams.
• Regulatory hurdles and patent litigation increase R&D costs.
• Market saturation from numerous generic manufacturers suppresses prices.

Summary of Key Data Points

Aspect	Details
Market size (2022)	$22 billion (Global, contraceptives segment)
CAGR for hormone therapy	4% (2023–2030)
Patent expiries	2010–2025 for major drugs
Emerging markets growth	>7% CAGR (Asia-Pacific, Latin America)
Patent filings (2020–2025)	15–20 filings/year, mostly for delivery systems

Key Takeaways

• Patent expiries between 2010 and 2025 led to increased generic competition, pressure on pricing.
• Innovation focuses on delivery methods and combination therapies.
• Emerging markets and long-acting formulations present growth opportunities.
• Patent litigation and regulatory policies remain critical influences on market dynamics.
• Increasing global demand in women’s health and aging populations sustains long-term growth prospects.

FAQs

1. When will major progestin patents expire?
   Most patents for primary progestins expired or will expire between 2010 and 2025, opening the sector for generics.

2. What are key innovations in progestin delivery?
   Extended-release implants, intrauterine devices, transdermal patches, and subdermal rods are primary innovations.

3. How does patent litigation affect the market?
   It can delay generic entry, increase R&D costs, and influence market exclusivity periods.

4. What emerging markets are promising for progestin drugs?
   Countries in Asia-Pacific, Latin America, and Africa show high growth potential due to demographic shifts and increasing healthcare access.

5. What are the main regulatory challenges?
   Variability in approval processes, data exclusivity rules, and patent enforcement influence product timelines and market competition.

---

References

1. Grand View Research. (2023). Contraceptive market analysis.
2. Research and Markets. (2023). Hormone therapy global outlook.
3. U.S. Food and Drug Administration. (2022). Regulatory guidance on hormonal drugs.
4. European Medicines Agency. (2022). Summary of product characteristics for progestin drugs.